Potential antidotes for reversal of old and new oral anticoagulants

Thrombosis Research

Volumn 133, Issue SUPPL. 2, 2014, Pages

  Suryanarayan, Deepa ^a,b   Schulman, Sam ^a  

^a MCMASTER UNIVERSITY   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

Author keywords

Antidote; Bleeding; Direct thrombin inhibitors; Factor Xa inhibitors; Heparin; Warfarin

Indexed keywords

ACTIVATED CARBON; ACTIVATED PROTHROMBIN COMPLEX; ANTICOAGULANT AGENT; ANTIDOTE; ANTIVITAMIN K; BLOOD CLOTTING FACTOR 10A INHIBITOR; BLOOD CLOTTING FACTOR 7A; DABIGATRAN; HEPARIN; PENTASACCHARIDE; PROTAMINE; PROTHROMBIN COMPLEX; RECOMBINANT BLOOD CLOTTING FACTOR 7A; THROMBIN INHIBITOR; VITAMIN K GROUP; WARFARIN; FIBRINOLYTIC AGENT;

ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; HALF LIFE TIME; HEMODIALYSIS; HEMOPERFUSION; HUMAN; NONHUMAN; PRIORITY JOURNAL; RISK FACTOR; ANTAGONISTS AND INHIBITORS; BLOOD; CHEMICALLY INDUCED; DRUG DEVELOPMENT; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ANTICOAGULANTS; DRUG DISCOVERY; FIBRINOLYTIC AGENTS; HEMORRHAGE; HUMANS; PROTAMINES; VITAMIN K;

EID: 84901417393     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/S0049-3848(14)50026-6     Document Type: Article

References (108)

1. A. Holbrook, S. Schulman, D.M. Witt, P.O. Vandvik, J. Fish, and M.J. Kovacs et al. Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines Chest 141 2012 e152S e184S
2. Y. Xu, A.M. Holbrook, C.S. Simpson, D. Dowlatshahi, and A.P. Johnson Prescribing patterns of novel oral anticoagulants following regulatory approval for atrial fibrillation in Ontario, Canada: A population-based descriptive analysis CMAJ Open 1 2013 E115 E119
3. I.Y. Gong, U.I. Schwarz, N. Crown, G.K. Dresser, A. Lazo-Langner, and G. Zou et al. Clinical and genetic determinants of warfarin pharmacokinetics and pharmacodynamics during treatment initiation PLoS One 6 2011 e27808
4. S.E. Kimmel, B. French, S.E. Kasner, J.A. Johnson, J.L. Anderson, and B.F. Gage et al. A pharmacogenetic versus a clinical algorithm for warfarin dosing N Engl J Med 369 2013 2283 2293
5. M. Pirmohamed, G. Burnside, N. Eriksson, A.L. Jorgensen, C.H. Toh, and T. Nicholson et al. A randomized trial of genotype-guided dosing of warfarin N Engl J Med 369 2013 2294 2303
6. T.I. Verhoef, G. Ragia, A. de Boer, R. Barallon, G. Kolovou, and V. Kolovou et al. A randomized trial of genotype-guided dosing of acenocoumarol and phenprocoumon N Engl J Med 369 2013 2304 2312
7. J. Hirsh, S.S. Anand, J.L. Halperin, and V. Fuster Guide to anticoagulant therapy: Heparin: A statement for healthcare professionals from the American Heart Association Circulation 103 2001 2994 3018 (Pubitemid 32578141)
8. S.B. Olsson Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial Lancet 362 2003 1691 1698 (Pubitemid 37468318)
9. J. Stangier, K. Rathgen, H. Stahle, D. Gansser, and W. Roth The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects Br J Clin Pharmacol 64 2007 292 303 (Pubitemid 47283865)
10. B. Eriksson, O. Dahl, M. Huo, A. Kurth, S. Hantel, and K. Hermansson et al. Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II) Thromb Haemost 105 2011 721 729
11. B.I. Eriksson, O.E. Dahl, N. Rosencher, A.A. Kurth, C.N. Van Dijk, and S.P. Frostick et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: A randomised, double-blind, non-inferiority trial Lancet 370 2007 949 956 (Pubitemid 47393577)
12. B.I. Eriksson, O.E. Dahl, N. Rosencher, A.A. Kurth, C.N. Van Dijk, and S.P. Frostick et al. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial J Thromb Haemost 5 2007 2178 2185 (Pubitemid 47617868)
13. S. Schulman, C. Kearon, A.K. Kakkar, P. Mismetti, S. Schellong, and H. Eriksson et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism N Engl J Med 361 2009 2342 2352
14. S. Schulman, C. Kearon, A.K. Kakkar, S. Schellong, H. Eriksson, and D. Baanstra et al. Extended use of dabigatran, warfarin or placebo in venous thromboembolism N Engl J Med 368 2013 709 718
15. S.J. Connolly, M.D. Ezekowitz, S. Yusuf, J. Eikelboom, J. Oldgren, and A. Parekh et al. Dabigatran versus warfarin in patients with atrial fibrillation N Engl J Med 361 2009 1139 1151
16. Samama MM. The mechanism of action of rivaroxaban - an oral, direct Factor Xa inhibitor - compared with other anticoagulants. Thromb Res 127:497-504
17. B.I. Eriksson, L.C. Borris, R.J. Friedman, S. Haas, M.V. Huisman, and A.K. Kakkar et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty N Engl J Med 358 2008 2765 2775 (Pubitemid 351930851)
18. A.K. Kakkar, B. Brenner, O.E. Dahl, B.I. Eriksson, P. Mouret, and J. Muntz et al. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: A double-blind, randomised controlled trial Lancet 372 2008 31 39
19. M.R. Lassen, W. Ageno, L.C. Borris, J.R. Lieberman, N. Rosencher, and T.J. Bandel et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty N Engl J Med 358 2008 2776 2786 (Pubitemid 351930852)
20. A.G. Turpie, M.R. Lassen, B.L. Davidson, K.A. Bauer, M. Gent, and L.M. Kwong et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): A randomised trial Lancet 373 2009 1673 1680
21. M.R. Patel, K.W. Mahaffey, J. Garg, G. Pan, D.E. Singer, and W. Hacke et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation N Engl J Med 365 2011 883 891
22. R. Bauersachs, S.D. Berkowitz, B. Brenner, H.R. Buller, H. Decousus, and A.S. Gallus et al. Oral rivaroxaban for symptomatic venous thromboembolism N Engl J Med 363 2010 2499 2510
23. H.R. Buller, M.H. Prins, A.W. Lensing, H. Decousus, B.F. Jacobson, and E. Minar et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism N Engl J Med 366 2012 1287 1297
24. M.R. Lassen, G.E. Raskob, A. Gallus, G. Pineo, D. Chen, and P. Hornick Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): A randomised double-blind trial Lancet 375 2010 807 815
25. M.R. Lassen, G.E. Raskob, A. Gallus, G. Pineo, D. Chen, and R.J. Portman Apixaban or enoxaparin for thromboprophylaxis after knee replacement N Engl J Med 361 2009 594 604
26. M.R. Lassen, A. Gallus, G.E. Raskob, G. Pineo, D. Chen, and L.M. Ramirez Apixaban versus enoxaparin for thromboprophylaxis after hip replacement N Engl J Med 363 2010 2487 2498
27. S.J. Connolly, J. Eikelboom, C. Joyner, H.C. Diener, R. Hart, and S. Golitsyn et al. Apixaban in patients with atrial fibrillation N Engl J Med 364 2011 806 817
28. C.B. Granger, J.H. Alexander, J.J. McMurray, R.D. Lopes, E.M. Hylek, and M. Hanna et al. Apixaban versus warfarin in patients with atrial fibrillation N Engl J Med 365 2011 981 992
29. G. Agnelli, H.R. Buller, A. Cohen, M. Curto, A.S. Gallus, and M. Johnson et al. Oral apixaban for the treatment of acute venous thromboembolism N Engl J Med 369 2013 799 808
30. The Hokusai-VTE Investigators Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism N Engl J Med 369 2013 1406 1415
31. R.P. Giugliano, C.T. Ruff, E. Braunwald, S.A. Murphy, S.D. Wiviott, and J.L. Halperin et al. Edoxaban versus warfarin in patients with atrial fibrillation N Engl J Med 369 2013 2093 2104
32. J.D. Douketis, K. Arneklev, S.Z. Goldhaber, J. Spandorfer, F. Halperin, and J. Horrow Comparison of bleeding in patients with nonvalvular atrial fibrillation treated with ximelagatran or warfarin: Assessment of incidence, case-fatality rate, time course and sites of bleeding, and risk factors for bleeding Arch Intern Med 166 2006 853 859
33. S. Schulman, R.J. Beyth, C. Kearon, and M.N. Levine Hemorrhagic complications of anticoagulant and thrombolytic treatment: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest 133 2008 257S 298S (Pubitemid 351892969)
34. M. Crowther, and W. Lim Low molecular weight heparin and bleeding in patients with chronic renal failure Curr Opin Pulm Med 13 2007 409 413 (Pubitemid 47472303)
35. S. Yusuf, S.R. Mehta, S. Chrolavicius, R. Afzal, J. Pogue, and C.B. Granger et al. Comparison of fondaparinux and enoxaparin in acute coronary syndromes N Engl J Med 354 2006 1464 1476
36. S. Yusuf, S.R. Mehta, S. Chrolavicius, R. Afzal, J. Pogue, and C.B. Granger et al. Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial JAMA 295 2006 1519 1530
37. A.G. Turpie, K.A. Bauer, B.I. Eriksson, and M.R. Lassen Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: A meta-analysis of 4 randomized double-blind studies Arch Intern Med 162 2002 1833 1840
38. J.W. Eikelboom, L. Wallentin, S.J. Connolly, M. Ezekowitz, J.S. Healey, and J. Oldgren et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: An analysis of the Randomized Evaluation of Long-term anticoagulant therapY (RE-LY) trial Circulation 123 2011 2363 2372
39. P.A. Reilly, T. Lehr, S. Haertter, S.J. Connolly, S. Yusuf, and J.W. Eikelboom et al. The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients in the RE-LY trial J Am Coll Cardiol 63 2014 321 328
40. S.J. Connolly, L. Wallentin, M.D. Ezekowitz, J. Eikelboom, J. Oldgren, and P.A. Reilly et al. The long-term multicenter observational study of dabigatran treatment in patients with atrial fibrillation (RELY-ABLE) study Circulation 128 2013 237 243
41. A.L. Dans, S.J. Connolly, L. Wallentin, S. Yang, J. Nakamya, and M. Brueckmann et al. Concomitant use of antiplatelet therapy with dabigatran or warfarin in the randomized evaluation of long-term anticoagulation therapy (RE-LY) trial Circulation 127 2013 634 640
42. J. Oldgren, M. Alings, H. Darius, H.C. Diener, J. Eikelboom, and M.D. Ezekowitz et al. Risks for stroke, bleeding, and death in patients with atrial fibrillation receiving dabigatran or warfarin in relation to the CHADS2 score: A subgroup analysis of the RE-LY trial Ann Intern Med 155 2011 660 667
43. J.L. Halperin, D. Wojdyla, J.P. Piccini, Y. Lokhnygina, M.R. Patel, and G. Breithardt et al. Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the ROCKET-AF Trial International Stroke Conference, New Orleans, LA 2012 Abstract 148
44. R.D. Lopes, S.M. Al-Khatib, L. Wallentin, H. Yang, J. Ansell, and M.C. Bahit et al. Efficacy and safety of apixaban compared with warfarin according to patient risk of stroke and of bleeding in atrial fibrillation: A secondary analysis of a randomised controlled trial Lancet 380 2012 1749 1758
45. B.D. Fox, S.R. Kahn, D. Langleben, M.J. Eisenberg, and A. Shimony Efficacy and safety of novel oral anticoagulants for treatment of acute venous thromboembolism: Direct and adjusted indirect meta-analysis of randomised controlled trials BMJ 345 2012 e7498
46. G.Y. Lip, T.B. Larsen, F. Skjoth, and L.H. Rasmussen Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation J Am Coll Cardiol 60 2012 738 746
47. F. Dentali, N. Riva, M. Crowther, A.G. Turpie, G.Y. Lip, and W. Ageno Efficacy and safety of the novel oral anticoagulants in atrial fibrillation: A systematic review and meta-analysis of the literature Circulation 126 2012 2381 2391
48. S. Chatterjee, P. Sardar, G. Biondi-Zoccai, and D.J. Kumbhani New oral anticoagulants and the risk of intracranial hemorrhage: traditional and bayesian meta-analysis and mixed treatment comparison of randomized trials of new oral anticoagulants in atrial fibrillation JAMA Neurol 70 2013 1486 1490
49. R.O. Bonow, B.A. Carabello, K. Chatterjee, A.C. de Leon Jr., D.P. Faxon, and M.D. Freed et al. 2008 Focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons Circulation 118 2008 e523 e661
50. M.A. Crowther, J.D. Douketis, T. Schnurr, L. Steidl, V. Mera, and C. Ultori et al. Oral vitamin K lowers the international normalized ratio more rapidly than subcutaneous vitamin K in the treatment of warfarin-associated coagulopathy. A randomized, controlled trial Ann Intern Med 137 2002 251 254
51. K.J. Dezee, W.T. Shimeall, K.M. Douglas, N.M. Shumway, and P.G. O'Malley Treatment of excessive anticoagulation with phytonadione (vitamin K): A meta-analysis Arch Intern Med 166 2006 391 397
52. H.G. Watson, T. Baglin, S.L. Laidlaw, M. Makris, and F.E. Preston A comparison of the efficacy and rate of response to oral and intravenous Vitamin K in reversal of over-anticoagulation with warfarin Br J Haematol 115 2001 145 149 (Pubitemid 32995108)
53. M.A. Crowther, W. Ageno, D. Garcia, L. Wang, D.M. Witt, and N.P. Clark et al. Oral vitamin K versus placebo to correct excessive anticoagulation in patients receiving warfarin: A randomized trial Ann Intern Med 150 2009 293 300
54. M.W. Swaim, and B.G. Macik Vitamin K to correct overanticoagulation Ann Intern Med 151 2009 432 433 author reply 435
55. M. Makris, M. Greaves, W.S. Phillips, S. Kitchen, F.R. Rosendaal, and E.F. Preston Emergency oral anticoagulant reversal: the relative efficacy of infusions of fresh frozen plasma and clotting factor concentrate on correction of the coagulopathy Thromb Haemost 77 1997 477 480 (Pubitemid 27121012)
56. L. Holland, T.E. Warkentin, M. Refaai, M.A. Crowther, M.A. Johnston, and R. Sarode Suboptimal effect of a three-factor prothrombin complex concentrate (Profilnine-SD) in correcting supratherapeutic international normalized ratio due to warfarin overdose Transfusion 49 2009 1171 1177
57. R. Sarode, T.J. Milling Jr., M.A. Refaai, A. Mangione, A. Schneider, and B.L. Durn et al. Efficacy and safety of a 4-factor prothrombin complex concentrate in patients on vitamin K antagonists presenting with major bleeding: A randomized, plasma-controlled, phase IIIb study Circulation 128 2013 1234 1243
58. F. Dentali, C. Marchesi, M.G. Pierfranceschi, M. Crowther, D. Garcia, and E. Hylek et al. Safety of prothrombin complex concentrates for rapid anticoagulation reversal of vitamin K antagonists A meta-analysis. Thromb Haemost 106 2011 429 438
59. D.K. Nishijima, W.E. Dager, R.J. Schrot, and J.F. Holmes The efficacy of factor VIIa in emergency department patients with warfarin use and traumatic intracranial hemorrhage Acad Emerg Med 17 2010 244 251
60. N.A. Pinner, A.C. Hurdle, C. Oliphant, A. Reaves, B. Lobo, and A. Sills Treatment of warfarin-related intracranial hemorrhage: A comparison of prothrombin complex concentrate and recombinant activated factor VII World Neurosurg 74 2010 631 635
61. S.A. Mayer, N.C. Brun, K. Begtrup, J. Broderick, S. Davis, and M.N. Diringer et al. Recombinant activated factor VII for acute intracerebral hemorrhage N Engl J Med 352 2005 777 785
62. K.A. O'Connell, J.J. Wood, R.P. Wise, J.N. Lozier, and M.M. Braun Thromboembolic adverse events after use of recombinant human coagulation factor VIIa JAMA 295 2006 293 298 (Pubitemid 43112957)
63. M. Levi, J.H. Levy, H.F. Andersen, and D. Truloff Safety of recombinant activated factor VII in randomized clinical trials N Engl J Med 363 2010 1791 1800
64. W.S. Stewart, and H. Pettit Experiences with an activated 4-factor prothrombin complex concentrate (FEIBA) for reversal of warfarin-related bleeding Am J Emerg Med 31 2013 1251 1254
65. C. Wojcik, M.L. Schymik, and E.G. Cure Activated prothrombin complex concentrate factor VIII inhibitor bypassing activity (FEIBA) for the reversal of warfarin-induced coagulopathy Int J Emerg Med 2 2009 217 225
66. M. Nybo, and J.S. Madsen Serious anaphylactic reactions due to protamine sulfate: A systematic literature review Basic Clin Pharmacol Toxicol 103 2008 192 196 (Pubitemid 352019729)
67. J.C. Horrow Protamine: A review of its toxicity Anesth Analg 64 1985 348 361 (Pubitemid 15130775)
68. T. Bakchoul, H. Zollner, J. Amiral, S. Panzer, S. Selleng, and T. Kohlmann et al. Anti-protamine-heparin antibodies: incidence, clinical relevance, and pathogenesis Blood 121 2013 2821 2827
69. S. Chan, M. Kong, D.M. Minning, U. Hedner, and V.J. Marder Assessment of recombinant factor VIIa as an antidote for bleeding induced in the rabbit by low molecular weight heparin J Thromb Haemost 1 2003 760 765
70. B. Lauritzen, U. Hedner, P.B. Johansen, M. Tranholm, and M. Ezban Recombinant human factor VIIa and a factor VIIa-analogue reduces heparin and low molecular weight heparin (LMWH)-induced bleeding in rats J Thromb Haemost 6 2008 804 811 (Pubitemid 351524541)
71. B. Lewis, M. O'Leary, and T. Vinh Successful use of rVIIa (NovoSeven) to reverse enoxaparin (Lovenox) overdose in an adult patient with intracranial bleeding Thromb Haemost Suppl 2001 2633 Abstr
72. N.R. Bijsterveld, A.H. Moons, S.M. Boekholdt, B.E. Van Aken, H. Fennema, and R.J. Peters et al. Ability of recombinant factor VIIa to reverse the anticoagulant effect of the pentasaccharide fondaparinux in healthy volunteers Circulation 106 2002 2550 2554 (Pubitemid 35340690)
73. N.R. Bijsterveld, R. Vink, B.E. Van Aken, H. Fennema, R.J. Peters, and J.C. Meijers et al. Recombinant factor VIIa reverses the anticoagulant effect of the long-acting pentasaccharide idraparinux in healthy volunteers Br J Haematol 124 2004 653 658 (Pubitemid 38297099)
74. K. Firozvi, R.A. Deveras, and C.M. Kessler Reversal of low-molecular-weight heparin-induced bleeding in patients with pre-existing hypercoagulable states with human recombinant activated factor VII concentrate Am J Hematol 81 2006 582 589 (Pubitemid 44066168)
75. G.T. Gerotziafas, F. Depasse, T. Chakroun, M.M. Samama, and I. Elalamy Recombinant factor VIIa partially reverses the inhibitory effect of fondaparinux on thrombin generation after tissue factor activation in platelet rich plasma and whole blood Thromb Haemost 91 2004 531 537 (Pubitemid 38396875)
76. T. Lisman, N.R. Bijsterveld, J. Adelmeijer, J.C. Meijers, M. Levi, and H.K. Nieuwenhuis et al. Recombinant factor VIIa reverses the in vitro and ex vivo anticoagulant and profibrinolytic effects of fondaparinux J Thromb Haemost 1 2003 2368 2373
77. G. Young, K.E. Yonekawa, P.A. Nakagawa, R.C. Blain, A.E. Lovejoy, and D.J. Nugent Recombinant activated factor VII effectively reverses the anticoagulant effects of heparin, enoxaparin, fondaparinux, argatroban, and bivalirudin ex vivo as measured using thromboelastography Blood Coagul Fibrinolysis 18 2007 547 553 (Pubitemid 47344302)
78. J.I. Weitz, D.J. Quinlan, and J.W. Eikelboom Periprocedural management and approach to bleeding in patients taking dabigatran Circulation 126 2012 2428 2432
79. F. Akwaa, and A.C. Spyropoulos Treatment of bleeding complications when using oral anticoagulants for prevention of strokes Curr Treat Options Cardiovasc Med 15 2013 288 298
80. M.P. Donadini, W. Ageno, and J.D. Douketis Management of bleeding in patients receiving conventional or new anticoagulants: A practical and case-based approach Drugs 72 2012 1965 1975
81. D.M. Siegal, and A. Cuker Reversal of novel oral anticoagulants in patients with major bleeding J Thromb Thrombolysis 35 2013 391 398
82. J. Van Ryn, J. Stangier, S. Haertter, K.H. Liesenfeld, W. Wienen, and M. Feuring et al. Dabigatran etexilate-a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity Thromb Haemost 103 2010 1116 1127
83. J.S. Woo, N. Kapadia, S.E. Phanco, and C.A. Lynch Positive outcome after intentional overdose of dabigatran J Med Toxicol 9 2013 192 195
84. J. Stangier, K. Rathgen, H. Stahle, and D. Mazur Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: An open-label, parallel-group, single-centre study Clin Pharmacokinet 49 2010 259 268
85. D. Khadzhynov, F. Wagner, S. Formella, E. Wiegert, V. Moschetti, and T. Slowinski et al. Effective elimination of dabigatran by haemodialysis. A phase I single-centre study in patients with end-stage renal disease Thromb Haemost 109 2013 596 605
86. B.C. Chen, N.R. Sheth, K.A. Dadzie, S.W. Smith, L.S. Nelson, and R.S. Hoffman et al. Hemodialysis for the treatment of pulmonary hemorrhage from dabigatran overdose Am J Kidney Dis 62 2013 591 594
87. Y. Lal, and J. Van Heukelom Dabigatran: A cause of hematologic emergency Am J Med Sci 346 2013 190 193
88. M.R. Wanek, E.T. Horn, S. Elapavaluru, S.C. Baroody, and G. Sokos Safe use of hemodialysis for dabigatran removal before cardiac surgery Ann Pharmacother 46 2012 e21
89. W. Zhou, S. Schwarting, S. Illanes, A. Liesz, M. Middelhoff, and M. Zorn et al. Hemostatic therapy in experimental intracerebral hemorrhage associated with the direct thrombin inhibitor dabigatran Stroke 42 2011 3594 3599
90. J. Van Ryn, M. Kink-Eiband, and A. Clemens The successful reversal of dabigatran-induced bleeding by coagulation factor concentrates in a rat tail bleeding model do not correlate with ex vivo markers of anticoagulation Blood 118 2011 Abstract 2316
91. E.S. Eerenberg, P.W. Kamphuisen, M.K. Sijpkens, J.C. Meijers, H.R. Buller, and M. Levi Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: A randomized, placebo-controlled, crossover study in healthy subjects Circulation 124 2011 1573 1579
92. A. Lillo-Le Louet, M. Wolf, L. Soufir, A. Galbois, A.S. Dumenil, and G. Offenstadt et al. Life-threatening bleeding in four patients with an unusual excessive response to dabigatran: implications for emergency surgery and resuscitation Thromb Haemost 108 2012 583 585
93. R. Marlu, E. Hodaj, A. Paris, P. Albaladejo, J.L. Crackowski, and G. Pernod Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban. A randomised crossover ex vivo study in healthy volunteers Thromb Haemost 108 2012 217 224
94. T.L. Khoo, C. Weatherburn, G. Kershaw, C.J. Reddel, J. Curnow, and S. Dunkley The use of FEIBA® in the correction of coagulation abnormalities induced by dabigatran Int J Lab Hematol 35 2013 222 224
95. W.E. Dager, R.C. Gosselin, and A.J. Roberts Reversing dabigatran in a life-threatening bleed occurring during cardiac ablation with factor eight inhibitor bypassing activity Crit Care Med 41 2013 e42 e46
96. S. Schulman, B. Ritchie, J.K. Goy, S. Nahirniak, M. Almutawa, and S. Ghanny Activated prothrombin complex concentrate for dabigatran-associated bleeding Br J Haematol 164 2014 608 610
97. T.E. Warkentin, P. Margetts, S. Connolly, A. Lamy, and C. Ricci Recombinant factor VIIa (rFVIIa) and hemodialysis to manage massive dabigatran-associated postcardiac surgery bleeding Blood 119 2012 2172 2174
98. F. Schiele, J. Van Ryn, K. Canada, C. Newsome, E. Sepulveda, and J. Park et al. A specific antidote for dabigatran: functional and structural characterization Blood 121 2013 3554 3562
99. D. Zhang, C.E. Frost, K. He, A.D. Rodrigues, X. Wang, and L. Wang et al. Investigating the enteroenteric recirculation of apixaban, a factor Xa inhibitor: Administration of activated charcoal to bile duct-cannulated rats and dogs receiving an intravenous dose and use of drug transporter knockout rats Drug Metab Dispos 41 2013 906 915
100. W. Zhou, M. Zorn, P. Nawroth, U. Butehorn, E. Perzborn, and S. Heitmeier et al. Hemostatic therapy in experimental intracerebral hemorrhage associated with rivaroxaban Stroke 44 2013 771 778
101. A. Godier, A. Miclot, B. Le Bonniec, M. Durand, A.M. Fischer, and J. Emmerich et al. Evaluation of prothrombin complex concentrate and recombinant activated factor VII to reverse rivaroxaban in a rabbit model Anesthesiology 116 2012 94 102
102. A.C. Martin, B. Le Bonniec, T. Lecompte, A.M. Fischer, J. Emmerich, and C.M. Samama et al. Evaluation of recombinant activated factor vii, prothrombin complex concentrate and fibrinogen concentrate to reverse apixaban in a rabbit model J Am Coll Cardiol 59 2012 E573 (Abstr 904-8)
103. T. Fukuda, Y. Honda, C. Kamisato, Y. Morishima, and T. Shibano Reversal of anticoagulant effects of edoxaban, an oral, direct factor xa inhibitor, with haemostatic agents Thromb Haemost 107 2012 253 259
104. A. Gruber, U.M. Marzec, U. Buetehorn, S. Hanson, and E. Perzborn Reversal of the antihaemostatic effects of rivaroxaban by activated factor vii and activated prothrombin complex in primates Haematologica 94 Suppl 2 2009 181 (Abstr 449)
105. G. Lu, F.R. DeGuzman, S.J. Hollenbach, M.J. Karbarz, K. Abe, and G. Lee et al. A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa Nat Med 19 2013 446 451
106. M. Crowther, V. Mathur, M. Kitt, G. Lu, P.B. Conley, and S. Hollenbach et al. A phase 2 randomized, double-blind, placebo-controlled trial demonstrating reversal of rivaroxaban-induced anticoagulation in healthy subjects by andexanet alfa (PRT064445), an antidote for FXa inhibitors Blood 122 2013 3636 (abstract)
107. B. Laulicht, S. Bakhru, C. Lee, C. Baker, X. Jiang, and E. Mathiowitz et al. Small molecule antidote for anticoagulants Circulation 126 2012 A11395 (abstract)
108. A. Majeed, H.-G. Hwang, S. Connolly, J. Eikelboom, M. Ezekowitz, and L. Wallentin et al. Management and outcomes of major bleeding on dabigatran or warfarin Circulation 128 2013 2325 2332